Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PrabotulinumtoxinA

            Therapeutic Area: Dermatology Product Name: Jeuveau

            Highest Development Status: Phase IV Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 24, 2021

            Details:

            The article focuses on pooled data from 492 Jeuveau®-treated patients who participated in two US multicenter, randomized, double-blind, placebo-controlled, single-dose phase III clinical studies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PrabotulinumtoxinA

            Therapeutic Area: Dermatology Product Name: Jeuveau

            Highest Development Status: Phase IV Product Type: Large molecule

            Partner/Sponsor/Collaborator: Daewoong Pharmaceutical

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 12, 2021

            Details:

            The two Phase II studies, conducted to support the registration and regulatory approval of Jeuveau® in the United States, Canada and Europe, demonstrate that prolonged use of Jeuveau is safe and effective with repeat treatments.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Botulinum toxin type A

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Phase IV Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 12, 2020

            Details:

            Top-line results showed that 95% of patients treated with Dysport were revealed from severe glabellar lines with two treatments per year, and for 97% the result of the treatment seemed natural.